Ken Kramer
Senior Vice President, Medical Affairs Helus Pharma
Ken Kramer, PhD, is a senior pharmaceutical executive with more than 25 years of experience across academic psychiatry, neuroscience research, and industry medical affairs leadership. He has led the medical strategy and launch of multiple innovative and first in class psychiatry therapies, including treatments for schizophrenia, bipolar disorder, and major depressive disorder. Dr. Kramer has held senior leadership roles at Allergan, Bristol Myers Squibb, Karuna Therapeutics, AbbVie, and currently, with Helus Pharma, building global medical affairs organizations and supporting assets from early development through commercialization. His work is grounded in a strong scientific foundation, with extensive peer reviewed publications in neuropharmacology and CNS disorders.
Seminars
Interventional psychiatry is advancing rapidly, but commercializing new treatments in this space requires navigating scientific complexity, clinical-workflow integration, regulatory ambiguity and evolving payer expectations. This workshop brings together leaders across drug development, clinical services, digital therapeutics and health-system innovation to unpack what it takes to bring interventional psychiatric treatments to market effectively and responsibly. Through real-world case studies and cross-sector perspectives, attendees will explore how to position novel modalities, build scalable delivery models, integrate biomarkers and patient-selection tools, evaluate reimbursement pathways, and ensure safe, consistent implementation across diverse clinical environments.
- Define the commercial, clinical and operational considerations required to bring interventional psychiatric treatments to market, including positioning, differentiation and workflow integration
- Examine the infrastructure, training, safety and scalability requirements needed for real-world delivery across clinics, health systems and community-based care settings
- Identify viable reimbursement and market-access pathways by understanding payer priorities, value demonstration, and the evidence needed to support sustainable adoption
